Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy.
Hypofraction
Intensive modulated radiotherapy
Paraganglioma
Pheochromocytoma
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
13
03
2022
accepted:
19
08
2022
pubmed:
20
9
2022
medline:
22
2
2023
entrez:
19
9
2022
Statut:
ppublish
Résumé
The purpose of this study was to review outcomes of patients with advanced/metastatic pheochromocytoma/paraganglioma (PPGL) treated at our institution with Intensity-modulated radiotherapy (IMRT), describe the treatment outcomes, and determine predictors. A retrospective study on patients with advanced/metastatic PPGL who received IMRT at Peking Union Medical College Hospital between 2014 and 2019. A total of 14 patients with 17 lesions were included in this study. Ultra-hypofractionated radiation therapy was used for 7 lesions in 5 patients, while hypofractionated radiation therapy was used for 8 lesions in 7 patients. 2 patients got conventional fractionated radiotherapy. Patients who received external beam radiation therapy were given a median total radiation dose of 74.4/130 Gy (BED10/3) in a median of 13 fractions. OS at 2 years was 78% for all patients. For lesions evaluated by RECIST response, at least stable disease of the target lesion was achieved in 94% and distant progression in 28.5%, with an average time to progression of 5.2 months. Patients with locally advanced primary tumors or recurred in situ (n = 8) achieved 100% local control, and none of them got recurrence or distant metastasis after radiotherapy at last follow-up (median 29 months). Of patients with catecholamine-related syndromes (n = 12), 91% of symptomatic lesions improved following radiation therapy and a more than 50% decline in catecholamines. We have found hypofractionated IMRT effective as an additional therapy for patients with advanced primary tumors or recurrence in situ and not amenable to complete surgical resection.
Identifiants
pubmed: 36121637
doi: 10.1007/s40618-022-01908-1
pii: 10.1007/s40618-022-01908-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
477-485Subventions
Organisme : grant from the Ministry of Science and Technology of China
ID : 2016YFC0105207
Organisme : Chinese Academy of Medical Sciences
ID : 2021-I2M-C&T-B-002
Organisme : Chinese Academy of Medical Sciences
ID : 2017-I2M-1-001
Informations de copyright
© 2022. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366(9486):665–675. https://doi.org/10.1016/S0140-6736(05)67139-5
doi: 10.1016/S0140-6736(05)67139-5
pubmed: 16112304
Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. https://doi.org/10.1210/jc.2014-1498
doi: 10.1210/jc.2014-1498
pubmed: 24893135
Klöppel G, Hruban R. 2017 WHO classification of tumours of endocrine organs: Lyon: International Agency for Research on Cancer 2017
Hamidi O, Young WF Jr, Gruber L et al (2017) Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 87(5):440–450. https://doi.org/10.1111/cen.13434
doi: 10.1111/cen.13434
pubmed: 28746746
De Filpo G, Cantini G, Rastrelli G et al (2022) Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience. J Endocrinol Invest 45(1):149–157. https://doi.org/10.1007/s40618-021-01629-x
doi: 10.1007/s40618-021-01629-x
pubmed: 34227051
Hadoux J, Favier J, Scoazec JY et al (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711–2720. https://doi.org/10.1002/ijc.28913
doi: 10.1002/ijc.28913
pubmed: 24752622
O’Kane GM, Ezzat S, Joshua AM et al (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120(12):1113–1119. https://doi.org/10.1038/s41416-019-0474-x
doi: 10.1038/s41416-019-0474-x
pubmed: 31105270
pmcid: 6738062
Fanciulli G, Di Molfetta S, Dotto A et al (2020) Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks. J Clin Med 10(1):88. https://doi.org/10.3390/jcm10010088[
doi: 10.3390/jcm10010088[
pubmed: 33383673
pmcid: 7795591
Satapathy S, Mittal BR, Bhansali A (2019) Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 91(6):718–727. https://doi.org/10.1111/cen.14106[
doi: 10.1111/cen.14106[
pubmed: 31569282
Lin F, Rivero JD, Carrasquillo JA, Jha A, Pacak K (2019) Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma. J Clin Oncol 37(15):TPS4159–TPS4259
doi: 10.1200/JCO.2019.37.15_suppl.TPS4159
Breen W, Bancos I, Young WF Jr et al (2018) External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3(1):25–29. https://doi.org/10.1016/j.adro.2017.11.002
doi: 10.1016/j.adro.2017.11.002
pubmed: 29556576
Vogel J, Atanacio AS, Prodanov T et al (2014) External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. Front Oncol 4:166. https://doi.org/10.3389/fonc.2014.00166
doi: 10.3389/fonc.2014.00166
pubmed: 25019060
pmcid: 4073229
Fishbein L, Bonner L, Torigian DA et al (2012) External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm Metab Res 44(5):405–410. https://doi.org/10.1055/s-0032-1308992
doi: 10.1055/s-0032-1308992
pubmed: 22566196
pmcid: 4357844
De Filpo G, Maggi M, Mannelli M, Canu L (2021) Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview. J Endocrinol Invest 44(1):15–25. https://doi.org/10.1007/s40618-020-01344-z
doi: 10.1007/s40618-020-01344-z
pubmed: 32602077
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-C
doi: 10.1016/0360-3016(95)00060-C
pubmed: 7713792
Batchu S, Hakim A, Henry OS et al (2022) Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. J Endocrinol Invest 45(5):989–998. https://doi.org/10.1007/s40618-021-01729-8
doi: 10.1007/s40618-021-01729-8
pubmed: 35088383